Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin

D. Carriero, Fabrizio Fabrizi, A. J. Uriel, J. Park, Paul Martin, D. T. Dieterich

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: No safe and effective therapy exists for chronic hepatitis C in dialysis patients. Available data on the antiviral treatment of hepatitis C in dialysis population is mostly based on standard interferon monotherapy. Objectives: We conducted a prospective, cohort trial with combined therapy (pegy1ated-interferon-alpha-2a (135 mcg/week) plus low dose ribavirin (200 mg/day)) for chronic hepatitis C in 15 patients undergoing long-term dialysis. Twelve patients had HCV genotype 1a/1b, three were co-infected with human immunodeficiency virus (HM, and two had compensated cirrhosis. End-points were sustained viral response and adverse effects. Results: Sustained virological response was obtained in four patients (including two with HCV genotype 1); the SVR rate was 28.6% (4/14), on an intention-to-treat analysis. One subject with SVR had compensated cirrhosis. All HIV co-infected patients had well controlled HIV and one of them (33%) reached SVR. Seven (50%) of the 14 patients were non-responders, two of which relapsed after discontinuation of therapy. Drop-out rate was 71.4% (10/14). The most frequent side-effect was anemia, which required ribovirin discontinuation in three patients; seven (47%) patients received blood transfusions. Two patients died (week 4 and 14) of causes related to cardiovascular disease, which was frequent in our cohort. Two subjects were hospitalized and discontinued therapy (week 1, and 27). Conclusions: Results from this study showed that about one-third of HD patients achieved sustained virological response with pegylated-interferon-alpha-2a plus low-dose ribavinin; however, tolerance to antiviral treatment was unsatisfactory. Well-controlled HIV infection should not be a contraindication to HCV therapy in dialysis patients. Prospective, controlled clinical trials of combined antiviral therapy targeted at HCV in chronic kidney disease population are indicated.

Original languageEnglish
Pages (from-to)295-302
Number of pages8
JournalInternational Journal of Artificial Organs
Volume31
Issue number4
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Interferons
Dialysis
Ribavirin
Chronic Hepatitis C
Antiviral Agents
Therapeutics
Viruses
Blood
HIV
Fibrosis
Genotype
Intention to Treat Analysis
Controlled Clinical Trials
Hepatitis C
Chronic Renal Insufficiency
Blood Transfusion
Population
HIV Infections
Anemia
Cardiovascular Diseases

Keywords

  • Chronic kidney disease
  • Dialysis
  • Hepatitis C
  • Pegylated interferon
  • Ribavirin

ASJC Scopus subject areas

  • Biophysics

Cite this

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. / Carriero, D.; Fabrizi, Fabrizio; Uriel, A. J.; Park, J.; Martin, Paul; Dieterich, D. T.

In: International Journal of Artificial Organs, Vol. 31, No. 4, 01.04.2008, p. 295-302.

Research output: Contribution to journalArticle

Carriero, D. ; Fabrizi, Fabrizio ; Uriel, A. J. ; Park, J. ; Martin, Paul ; Dieterich, D. T. / Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. In: International Journal of Artificial Organs. 2008 ; Vol. 31, No. 4. pp. 295-302.
@article{147fab63cbd44ed082356aa01f41136a,
title = "Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin",
abstract = "Background: No safe and effective therapy exists for chronic hepatitis C in dialysis patients. Available data on the antiviral treatment of hepatitis C in dialysis population is mostly based on standard interferon monotherapy. Objectives: We conducted a prospective, cohort trial with combined therapy (pegy1ated-interferon-alpha-2a (135 mcg/week) plus low dose ribavirin (200 mg/day)) for chronic hepatitis C in 15 patients undergoing long-term dialysis. Twelve patients had HCV genotype 1a/1b, three were co-infected with human immunodeficiency virus (HM, and two had compensated cirrhosis. End-points were sustained viral response and adverse effects. Results: Sustained virological response was obtained in four patients (including two with HCV genotype 1); the SVR rate was 28.6{\%} (4/14), on an intention-to-treat analysis. One subject with SVR had compensated cirrhosis. All HIV co-infected patients had well controlled HIV and one of them (33{\%}) reached SVR. Seven (50{\%}) of the 14 patients were non-responders, two of which relapsed after discontinuation of therapy. Drop-out rate was 71.4{\%} (10/14). The most frequent side-effect was anemia, which required ribovirin discontinuation in three patients; seven (47{\%}) patients received blood transfusions. Two patients died (week 4 and 14) of causes related to cardiovascular disease, which was frequent in our cohort. Two subjects were hospitalized and discontinued therapy (week 1, and 27). Conclusions: Results from this study showed that about one-third of HD patients achieved sustained virological response with pegylated-interferon-alpha-2a plus low-dose ribavinin; however, tolerance to antiviral treatment was unsatisfactory. Well-controlled HIV infection should not be a contraindication to HCV therapy in dialysis patients. Prospective, controlled clinical trials of combined antiviral therapy targeted at HCV in chronic kidney disease population are indicated.",
keywords = "Chronic kidney disease, Dialysis, Hepatitis C, Pegylated interferon, Ribavirin",
author = "D. Carriero and Fabrizio Fabrizi and Uriel, {A. J.} and J. Park and Paul Martin and Dieterich, {D. T.}",
year = "2008",
month = "4",
day = "1",
language = "English",
volume = "31",
pages = "295--302",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin

AU - Carriero, D.

AU - Fabrizi, Fabrizio

AU - Uriel, A. J.

AU - Park, J.

AU - Martin, Paul

AU - Dieterich, D. T.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: No safe and effective therapy exists for chronic hepatitis C in dialysis patients. Available data on the antiviral treatment of hepatitis C in dialysis population is mostly based on standard interferon monotherapy. Objectives: We conducted a prospective, cohort trial with combined therapy (pegy1ated-interferon-alpha-2a (135 mcg/week) plus low dose ribavirin (200 mg/day)) for chronic hepatitis C in 15 patients undergoing long-term dialysis. Twelve patients had HCV genotype 1a/1b, three were co-infected with human immunodeficiency virus (HM, and two had compensated cirrhosis. End-points were sustained viral response and adverse effects. Results: Sustained virological response was obtained in four patients (including two with HCV genotype 1); the SVR rate was 28.6% (4/14), on an intention-to-treat analysis. One subject with SVR had compensated cirrhosis. All HIV co-infected patients had well controlled HIV and one of them (33%) reached SVR. Seven (50%) of the 14 patients were non-responders, two of which relapsed after discontinuation of therapy. Drop-out rate was 71.4% (10/14). The most frequent side-effect was anemia, which required ribovirin discontinuation in three patients; seven (47%) patients received blood transfusions. Two patients died (week 4 and 14) of causes related to cardiovascular disease, which was frequent in our cohort. Two subjects were hospitalized and discontinued therapy (week 1, and 27). Conclusions: Results from this study showed that about one-third of HD patients achieved sustained virological response with pegylated-interferon-alpha-2a plus low-dose ribavinin; however, tolerance to antiviral treatment was unsatisfactory. Well-controlled HIV infection should not be a contraindication to HCV therapy in dialysis patients. Prospective, controlled clinical trials of combined antiviral therapy targeted at HCV in chronic kidney disease population are indicated.

AB - Background: No safe and effective therapy exists for chronic hepatitis C in dialysis patients. Available data on the antiviral treatment of hepatitis C in dialysis population is mostly based on standard interferon monotherapy. Objectives: We conducted a prospective, cohort trial with combined therapy (pegy1ated-interferon-alpha-2a (135 mcg/week) plus low dose ribavirin (200 mg/day)) for chronic hepatitis C in 15 patients undergoing long-term dialysis. Twelve patients had HCV genotype 1a/1b, three were co-infected with human immunodeficiency virus (HM, and two had compensated cirrhosis. End-points were sustained viral response and adverse effects. Results: Sustained virological response was obtained in four patients (including two with HCV genotype 1); the SVR rate was 28.6% (4/14), on an intention-to-treat analysis. One subject with SVR had compensated cirrhosis. All HIV co-infected patients had well controlled HIV and one of them (33%) reached SVR. Seven (50%) of the 14 patients were non-responders, two of which relapsed after discontinuation of therapy. Drop-out rate was 71.4% (10/14). The most frequent side-effect was anemia, which required ribovirin discontinuation in three patients; seven (47%) patients received blood transfusions. Two patients died (week 4 and 14) of causes related to cardiovascular disease, which was frequent in our cohort. Two subjects were hospitalized and discontinued therapy (week 1, and 27). Conclusions: Results from this study showed that about one-third of HD patients achieved sustained virological response with pegylated-interferon-alpha-2a plus low-dose ribavinin; however, tolerance to antiviral treatment was unsatisfactory. Well-controlled HIV infection should not be a contraindication to HCV therapy in dialysis patients. Prospective, controlled clinical trials of combined antiviral therapy targeted at HCV in chronic kidney disease population are indicated.

KW - Chronic kidney disease

KW - Dialysis

KW - Hepatitis C

KW - Pegylated interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=45949096855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949096855&partnerID=8YFLogxK

M3 - Article

C2 - 18432584

AN - SCOPUS:45949096855

VL - 31

SP - 295

EP - 302

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 4

ER -